<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01714297</url>
  </required_header>
  <id_info>
    <org_study_id>REK Sør-øst s-08012d</org_study_id>
    <nct_id>NCT01714297</nct_id>
  </id_info>
  <brief_title>Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)</brief_title>
  <official_title>A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martina Hansen's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martina Hansen's Hospital</source>
  <oversight_info>
    <authority>Norway: Directorate of Health</authority>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there are differences in clinical events, i.e
      bleeding with associated morbidity, if thromboprophylaxis with LMWH (Low Molecular Weight
      Heparin) is initiated before or after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>total blood loss</measure>
    <time_frame>during and after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measured blood loss during surgery and in wound drains</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>transfusion requirements</measure>
    <time_frame>during and after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of units packed red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of bleeding events</measure>
    <time_frame>during and after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>excessive bleeding, wound hematoma, wound secretion, other bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other complications</measure>
    <time_frame>during and after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>all other complications related to surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Arthritis of the Hip</condition>
  <condition>Transfusion Related Complications</condition>
  <condition>Infection</condition>
  <condition>Wound Discharge</condition>
  <arm_group>
    <arm_group_label>dalteparin 5000IU s.c.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalteparin 5000 IU s.c.</intervention_name>
    <description>All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.</description>
    <arm_group_label>dalteparin 5000IU s.c.</arm_group_label>
    <arm_group_label>saline</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -patients 50 years or older undergoing cemented total hip arthroplasty for primary
        osteoarthritis

        Exclusion Criteria:

          -  allergy to Low-Molecular-Weight -Heparin

          -  bleeding disorders

          -  renal failure

          -  hepatic disease

          -  active treatment for malignancy

          -  history of deep venous thrombosis or pulmonary embolism

          -  major operations,trauma,stroke or cardiac infarction the last 3 months before
             surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Reikeras, MD, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Martina Hansen's Hospital</name>
      <address>
        <city>Sandvika</city>
        <state>Gjettum</state>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Borgen PO, Dahl OE, Reikerås O. Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res. 2012 Sep;470(9):2591-8. doi: 10.1007/s11999-012-2320-9. Epub 2012 Apr 3.</citation>
    <PMID>22476844</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 7, 2012</lastchanged_date>
  <firstreceived_date>October 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martina Hansen's Hospital</investigator_affiliation>
    <investigator_full_name>Pål Borgen, MD</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <keyword>cemented total hip arthroplasty</keyword>
  <keyword>blood loss</keyword>
  <keyword>wound discharge</keyword>
  <keyword>thromboprophylaxis</keyword>
  <keyword>biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
